{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m nalidixic acid
to a specific field?
Status:
Investigational
Source:
NCT01806675: Phase 1/Phase 2 Interventional Completed Adult Giant Cell Glioblastoma
(2013)
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Status:
Investigational
Source:
Int J Hematol. Nov 2022;116(5):754-769.: Phase 1 Human clinical trial Completed Graft vs Host Disease/therapy
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:asengeprast [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT04071184: Phase 1 Interventional Unknown status Gastric Cancer
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Russian Pharmaceutical Technologies is developing alofanib, a first in class, allosteric inhibitor of fibroblast growth factor receptor type 2 (FGFR2) for the treatment of tumours expressing FGFR2, including ovarian cancer, colorectal cancer and lung cancer. Alofanib is a potential allosteric inhibitor of FGFR2 used in oncology. Alofanib has potent effects on ovarian cancer growth in preclinical studies.The inhibitor blocks the extracellular part of the receptor and prevents its binding with the ligand. Alofanib suppressed proliferation of endothelial cells, their migration activity, and ability to form vessellike structures in vitro and significantly decreased the number of microvessels in Matrigel implant and in ovarian cancer (SKOV-3) xenograft in vivo. The results indicate that Alofanib can inhibit angiogenesis.
Status:
Investigational
Source:
NCT00635804: Phase 1 Interventional Completed Hepatitis C
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
MK-3281 is a potent and orally bioavailable inhibitor of HCV NS5B polymerase which combined excellent cell-based potency with good pharmacokinetic properties in preclinical species. MK-3281 was efficacious in the chimeric mouse model of HCV infection.
Status:
Investigational
Source:
INN:vidoflufolastat (18f) [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02295592: Not Applicable Interventional Unknown status Hemorrhoids
(2014)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Source:
NCT03804879: Phase 2 Interventional Completed Diabetic Nephropathy
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT04454918: Phase 1 Interventional Completed Healthy Volunteers
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03644264: Phase 3 Interventional Completed Chronic Kidney Disease Requiring Chronic Dialysis
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
